<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Manganese-enhanced MRI of hypoxic-ischemic brain injuries using Mn-DPDP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Yang, J; Wu, EX</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>The 31st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2009), Minneapolis, MN., 3-6 September 2009. In Proceedings of the 31st EMBC, 2009, p. 4775-4778</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2009</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/129726">http://hdl.handle.net/10722/129726</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Creative Commons: Attribution 3.0 Hong Kong License</td>
</tr>
</tbody>
</table>
Manganese-Enhanced MRI of Hypoxic-Ischemic Brain Injuries using Mn-DPDP

Jian Yang and Ed X. Wu

Abstract: In this study, Mn-dipyridoxaldiphosphate (MnDPDP), a clinically approved manganese contrast agent for hepatic and pancreatic imaging, was demonstrated for the first time for manganese-enhanced MRI (MEMRI) in brains of normal young rats (n=4) and rats with hypoxic-ischemic (H-I) insult at postnatal day 7 (n=8). A single intraperitoneal injection of low dosage with 0.1μmol/g in postnatal 14 days, 2D T1-weighted image (T1WIs), T1 maps, T2-weighted images (T2WIs) and T2 maps were acquired at 7 Tesla 1 day before, 1 day and 7 days after MnDPDP injection. The image contrast changes induced by MnDPDP appeared as the hyperintensity in T1WIs and the hypointensity in T2WIs. T1 and T2 values decreased in the regions of Mn enhancement. Such enhancement presented as a delayed pattern that was more pronounced in 7 day after MnDPDP injection, suggesting the sustained Mn accumulation due to MnDPDP. Moreover, the MnDPDP enhancement in H-I brains was more pronounced in the lesion sites and was easily detectable in T1WI, T1 map, T2WI and T2 map. The results demonstrated here support the possibility of using MnDPDP as a ‘slow release’ Mn$^{2+}$ for clinical diagnosis of various neuropathologies.

I. INTRODUCTION

Divalent manganese ion (Mn$^{2+}$) as an analogue for calcium ion (Ca$^{2+}$) has been used as a MRI contrast agent to detect neuronal activation [1, 2], neural architecture [3, 4], and neuronal connections [5, 6]. It is also essential to the development and function of the brain in physiological and pathological states [7-10]. Mn metal is bound to glutamine synthetase (GS) which is a glial specific enzyme for regulating the extracellular glutamate and ammonia. It can also reduce glutamate excitotoxicity [11-13] and to the mitochondrial Mn-superoxide dismutase (Mn-SOD) enzyme which acts against cellular oxidative stress [11, 14, 15]. Therefore, a previous study found that endogenous Mn in the form of Mn-SOD and GS were accumulated in delayed neurodegenerated regions and could be detected by MRI in adult rat and human after experiencing stroke [11]. Recently, our studies demonstrated that exogenous Mn could provide enhanced MRI detection of oxidative stress and gliosis in neonatal rats with hypoxia-ischemia (H-I) and adult rats with focal photothermotic cortical injury and transient middle cerebral artery occlusion [16-18]. Especially the upregulation of MnSOD and GS activities in gray matter delayed to detectable by other MR modalities [18]. It suggests the potential usage of MEMRI by Mn$^{2+}$ agent for clinical diagnosis of various neuropathologies.

Although neurotoxicity is a critical barrier to application of Mn$^{2+}$ as a useful MRI contrast agent in clinical diagnosis, a chelated Mn$^{2+}$ contrast agent, Mn-dipyridoxaldiphosphate (MnDPDP), is necessary to decrease the high acute toxicity of the free metal ions. It has been clinically approved for hepatic and pancreatic imaging for several years [19, 20], and also for assessments of myocardial function and viability in animal models [21]. This chelate gradually releases Mn$^{2+}$ in presence of trans-metallation with zinc which is a Mn analog, allowing the detection of abnormalities by Mn$^{2+}$ enhancement. MnDPDP has also been shown of certain virtue with antioxidative and cardioprotective properties [22]. In this study, we attempt to test the feasibility of delayed MnDPDP administration for detection of cerebral degeneration in H-I rats. It may open the possibility of a future study of MnDPDP as a ‘slow release’ Mn$^{2+}$ agent for clinical diagnosis of various neuropathologies.

II. MATERIALS AND METHODS

Animal preparation

All animal experiments were approved by the local animal research ethics committee. Pregnant Sprague–Dawley rats were obtained approximately 2 days before parturition, and their litters were culled to 9 to 13 pups. Neonate rats were kept with their mother in regular light/dark cycle for 7 days after birth (P7). The P7 rats, ranging from 12 to 16 g in weight, underwent unilateral ligation of right common carotid artery (double ligation followed by severing the artery in between) via a midline neck incision after anesthesia with 0.2 mL of inhalational isoflurane [17, 23-25]. The surgery took approximately 5 min per pup, after which the pups were kept in an incubator for observation at 34 °C for about 10–15 min. On regaining normal movements, they were returned to their...
mother for nursing for 1 h. These pups were subsequently placed in a hypoxic chamber of 8% O₂/92% N₂ maintained at ambient temperatures 36 °C for 1.5 h. Among a total of 16 P7 rats, 12 rats underwent H-I insult, among which four died during surgery or anoxia. Four rats were used as sham-operated controls; their left carotid artery was simply isolated and there was no exposure to hypoxia. The neonatal rats (N =12) were then divided into two groups. Group 1 (N =8): H-I insult with intraperitoneal (IP) MnDPDP administration; Group 2 (N = 4): sham controls (without H-I insult) with IP MnDPDP administration. MnDPDP with 10μmol/mL (Teslascan®, Nycomed Imaging AS, Oslo, Norway) was injected at dosage of 0.1μmol/g by intraperitoneal route in P14 while the rats were anesthetized with 1% isoflurane mixed with room air. This dosage is far lower than the human dosage (5μmol/kg) according to converted method of body surface area calculation (equivalent dosage ratio between the human and P14 young rat is approximately 378). Among all rats undergoing MnDPDP administration, no abnormal behavior was observed after IP injection.

MRI protocol

All MRI experiments were performed on a 7-Tesla MRI scanner with maximum gradient of 360 mT/m (70/16 PharmaScan, Bruker Biospin GmbH, Germany) using a 23 mm mouse brain coil (for rats of 3 weeks old or younger) and a 38 mm rat brain coil (for rats older than 3 weeks). During the MRI scan, the rats were positioned in a plastic holder and anesthetized by isoflurane (1–1.5vol % at 0.8–1 L/min air flow via a nose cone) with respiratory monitoring. 2D T₁-weighted images (T₁WIs), T1 maps, T₂-weighted images (T₂WIs) and T2 maps were scanned in succession in P10, P14, P15, P21. Standard multislice coronal images were obtained with FOV= 2.5 cm, slice thickness= 0.5 mm, matrix size= 256 ×256, voxel size= 98μm×98μm×500μm, and 20 slices. T1WI were acquired by a fast spin echo (FSE) sequence with TR= 500 ms, TEeff =7 ms, echo train length (ETL)= 2, number of averages (NSA)= 6, and acquisition time= 5 min. T2WI were acquired using an FSE sequence with TR = 6000 ms, TEeff = 60 ms, ETL= 12, NSA= 2, and acquisition time= 3 min. The T2 maps were acquired by a multislice and multiecho SE sequence, Bandwidth= 65789Hz, TR= 3450ms, Echo effective= 10 ms, Echo spacing= 10 ms, Number of echo= 16, NSA= 1, Scan time= 11min. The corresponding T1 maps were acquired by a saturation recovery method with a standard multislice spin-echo sequence, Bandwidth=83333Hz, Five different TR values= 3200, 1600, 800, 400 and 200 ms, TE= 7.2 ms, NSA= 1, Spatial resolution= 98 ×125μm/pixel, FOV= 2.5 × 2.5 cm, slice thickness= 1 mm, matrix= 200 × 256, scan time= 15min30sec.

Data analysis

Images were analyzed using the public domain software ImageJ (National Institutes of Health [NIH], Washington, DC, USA) and ParaVision (Bruker Biospin GmbH, Germany). Region of interest (ROI) analysis of the T1 maps and T2 map was performed and defined in specific brain regions after comparing the coronal images with a rat brain atlas. Three brain regions were analyzed: hippocampus, thalamus, and cortex. Mean values were compared using two-tailed Student’s t-tests, and the values along the time course were compared using ANOVA. Results were considered to be significantly different when p<0.05. All statistical analyses were performed by using the statistical package SPSS for Windows (SPSS Inc., IL, USA). The results were presented as mean±SEM.

III. RESULTS AND DISCUSSION

MEMRI in normal young rats by IP injection of MnDPDP

After 1 day post-MnDPDP-injection, the contrast and signal enhancement were observed throughout the brain in T1WI images, suggesting Mn²⁺ release by MnDPDP was distributed throughout the brain. Higher contrast was observed in the periventricular regions, caudate-putamen, thalamus, the hippocampus, the olfactory bulb and cerebellum, which was consistent with a previous study regarding MEMRI in young rat brain during postnatal development[26]. In this study, the shortened percents of T1 value in cortex, thalamus and hippocampus were 10.4%, 17.3% and 15.5% respectively in 1 day post-MnDPDP-injection. Such changes in T1 value were statistically significant (ANOVA, p>0.05) when compared to the same regions in the normal rats before MnDPDP injection (see Fig.1). However, these MnDPDP-induced changes were noticeably smaller than the reports in several previous studies [26, 27], which are related to the low dosage regarding MEMRI in young rat brain during postnatal development[26]. In this study, the shortened percents of T1 value in cortex, thalamus and hippocampus were 10.4%, 17.3% and 15.5% respectively in 1 day post-MnDPDP-injection. Such changes in T1 value were statistically significant (ANOVA, p>0.05) when compared to the same regions in the normal rats before MnDPDP injection (see Fig.1). However, these MnDPDP-induced changes were noticeably smaller than the reports in several previous studies [26, 27], which are related to the low dosage regarding MEMRI in young rat brain during postnatal development[26]. In this study, the shortened percents of T1 value in cortex, thalamus and hippocampus were 10.4%, 17.3% and 15.5% respectively in 1 day post-MnDPDP-injection. Such changes in T1 value were statistically significant (ANOVA, p>0.05) when compared to the same regions in the normal rats before MnDPDP injection (see Fig.1). However, these MnDPDP-induced changes were noticeably smaller than the reports in several previous studies [26, 27], which are related to the low dosage regarding MEMRI in young rat brain during postnatal development[26].

MEMRI detection of Neurodegeneration in H-I young rats by IP injection of MnDPDP

All 8 neonatal rats induced with medium H–I injury exhibited lesions on the parietal cortex and striatum with distinct atrophy in the hemisphere ipsilateral to carotid artery...
ligation side (see Fig. 3). At day 7 after H-I insult (P14), the lesion sites could not be detected in T1WIs before MnDPDP administration. But some lesions in subcortical white matter were presented as hyperintensity in T2WIs and T2 maps (the red arrows in Fig. 3), which was consistent with a previous study [29]. Moreover, some weak dark contrast also appeared in the ipsilateral cortex (the yellow arrows in Fig. 3) and/or striatum in T2WIs and T2 maps, which is likely resulted from the endogenous iron accumulation due to an abnormal iron metabolism in HI injury [17]. Such decreases in T2 value were statistically significant ($t$ test, $p>0.001$) when compared to the same regions in the contralateral side (see Fig. 4).

At 1 day after MnDPDP injection (P15), some weak bright regions became visible in ipsilateral cortex and striatum in T1WIs, suggesting MnDPDP induced enhancement, and that most spatially corresponded to regions with new dark contrast in T1 maps, T2WIs and T2 maps (the white arrows indicated in middle two rows of Fig. 3). Moreover, the decreases of T1 value in ipsilateral cortex and thalamus were statistically significant (ANOVA, $p>0.001$) when compared to the same regions prior to MnDPDP injection (see Fig. 5). However, such decreases of T2 value were not statistically significant different in comparison with the data before MnDPDP injection (Fig. 4). It suggests that MnDPDP induced change in T1 value is more significant than it is in T2 value.

After 7 days post-MnDPDP-injection (P21), the Mn$^{2+}$ induced contrast changes in ipsilateral cortex and striatum were further enhanced in T1WIs, T1 maps, T2WIs and T2 maps (the white arrows indicated in below two rows of Fig. 3). In Fig. 5, the further decreases of T1 value in ipsilateral cortex and thalamus were statistically significant when compared to the same regions in 1 day after MnDPDP injection (ANOVA, $p>0.001$) and in the contralateral side ($t$ test, $p>0.0001$). The shortened percents of T1 value in lesion of ipsilateral cortex and thalamus were 29.6% and 41.7% respectively in 7 days.
post-MnDPDP-injection and the decreases in T1 value were statistically significant (ANOVA, p<0.0001) when compared to the same regions before MnDPDP injection (see Fig.5). Moreover, such decreases of T2 value were statistically significant different in comparison with the data before MnDPDP injection (see Fig.4). It suggests that Mn accumulation from MnDPDP in lesion sites is sustained and MEMRI for detection of H-I lesion sites in 7 days post-MnDPDP-injection is more pronounced than it is in 1 day post-MnDPDP-injection.

IV. CONCLUSION

In this study, MnDPDP as a clinically approved manganese contrast medium for hepatic and pancreatic imaging was employed for the first time for MEMRI in both normal and H-I young rat brains. After a single intraperitoneal injection of low dose at 0.1μmol/g, Manganese enhancement induced by MnDPDP was observed as delayed pattern and more pronounced in 7 days post-injection. Moreover, such Mn accumulation from MnDPDP in H-I brains was pronounced in the H-I lesion sites and was detectable in T1WI, T1 map, T2WI and T2 map. The results demonstrated here support the possibility of using MnDPDP as a ‘slow release’ Mn²⁺ agent for clinical diagnosis of various neurodegenerative diseases in the future.

REFERENCES


